NCT07054567 2026-01-21
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
Clinical Trials
18 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT04868708 2025-03-04
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
Phase 2 Completed
NCT03367871 2024-06-18
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
Phase 2 Terminated
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT02921269 2023-02-21
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT05247619 2022-07-15
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05444374 2022-07-05
A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT04974944 2021-10-01
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04973904 2021-07-22
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT00025233 2019-07-24
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
Phase 2 Completed
NCT02467907 2019-06-03
Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT03912402 2019-05-09
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
Biocad
Phase 2 Unknown
NCT00600210 2017-08-23
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Leo W. Jenkins Cancer Center
Phase 2 Withdrawn
NCT00545792 2017-03-15
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00548418 2014-08-01
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00626561 2014-07-07
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
M.D. Anderson Cancer Center
Phase 2 Terminated